Trends in the characteristics of vitrectomy in Eastern China

Fang, Yuan; Ku, Hsiangyu; Liu, Yiwen; Gan, Dekang

doi:10.2147/opth.s173251

Cited by 4 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperative inflammation is the major mechanism underlying early-onset open-angle ocular hypertension after vitrectomy, which is similar to uveitic glaucoma. Moreover, PGAs have been reported to be widely used to treat ocular hypertension after vitrectomy in clinical practice 6,23. However, there are no controlled clinical studies evaluating PGA in the treatment of early-stage ocular hypertension secondary to vitrectomy.…”

Section: Introductionmentioning

confidence: 99%

<p>Efficacy And Safety Of Travoprost Versus Timolol To Treat Early-Onset Ocular Hypertension Secondary To Vitrectomy: A Randomized Trial</p>

Fang

Gan

et al. 2019

DDDT

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy and safety of travoprost 0.004% versus timolol 0.5% as an initial intraocular pressure (IOP)-lowering medication for ocular hypertension secondary to vitrectomy.Patients and methodsWe performed a randomized, controlled, observer-blinded clinical trial in the Eye & ENT Hospital of Fudan University in China. This trial was registered at www.chictr.org.cn (ChICTR1800014942) before patient enrollment. Seventy-nine adults with IOP of 25–45 mmHg secondary to vitrectomy in the latest one month were enrolled and randomized to receive travoprost 0.004% or timolol 0.5%. More drugs were administered to patients with IOP > 25 mmHg during follow-up.ResultsThe mean IOP reduction at day 1 was −10.97 mmHg in the timolol group and −15.02 mmHg in the travoprost group (P = 0.006); no significant difference was observed between the groups at later time points. The number of IOP-lowering medications at day 21 was 0.64 in the timolol group and 1.15 in the travoprost group (P = 0.038), while no significant differences were observed at other time points. The proportion of single IOP-lowering medications used during the 4-week follow-up was 72.73% in the timolol group and 68.42% in the travoprost group (P = 0.692). Inflammation scores were not significantly different in the two groups at any time point. Increased ocular hyperemia occurred in 8 patients (19%) in the travoprost group and none in the timolol group (P = 0.005). There were no significant differences in other adverse events between the two groups. After logistic regression model analysis, IOP ≥ 30 mmHg, inflammation score ≥ 2, and silicone oil as tamponade were found to be the factors with significant effects on the number of IOP-lowering medications used during the 4-week follow-up.ConclusionTravoprost and timolol have similar efficacy and safety for treating ocular hypertension secondary to vitrectomy.

show abstract

Section: Introductionmentioning

confidence: 99%